



**The ACME Laboratories Ltd.**  
MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001: 2015 CERTIFIED COMPANY

o/c

Ref. No. ACME /CA/CS/0049/2020

07 June 2020

**The Chairman**

Bangladesh Securities and Exchange Commission  
Securities Commission Bhaban  
E-C/6, Agargaon,  
Sher-e-Bangla Nagar Administrative Area,  
Dhaka-1207.

**Subject: Audited Status Report on utilization of Initial Public Offering Proceeds for the Month ended 31 March 2020 of The ACME Laboratories Ltd.**

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering Proceeds for the Month ended 31 March 2020 of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 115<sup>th</sup> Meeting (through Digital Platform) held on 06 June 2020 for your kind perusal and record please.

It is to be mentioned here that due to country-wide effect of Coronavirus and afterwards declaration of public holiday by the government of People's Republic of Bangladesh, we were not in a position to complete the necessary compliance in time. However, in compliance with the Order of Bangladesh Securities and Exchange Commission (BSEC) vide order no. BSEC/CMRRCD/2009-193/06; dated: 2 June 2020, we are pleased to send herewith the above mentioned status report for your kind information.

Thanking you and assuring of our best attention for all the time to come.

  
**Mizanur Rahman Sinha**  
Managing Director

**Enclosure:** As stated above

Copy to: 01. The Managing Director, Dhaka Stock Exchange Limited  
02. The Managing Director, Chittagong Stock Exchange Limited  
03. The Chief Executive Officer, ICB Capital Management Limited



# Auditors' Report

## Name of Client

**The ACME Laboratories Ltd.**  
**Utilization of IPO Proceeds**

for the month ended 31 March 2020



**Registered Office:** AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh.  
Tel: +08802-966-0944, +8802-966-5095, Cell: +8801711-106302, +881534-130750.  
E-mail: pinaki\_co@yahoo.com website: www.pinaki.com.bd



## AUDITORS' REPORT

ON

### Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of The ACME Laboratories Ltd. for the month ended 31 March 2020.

#### Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

#### Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 31 March 2020 and comply with the resolution of 42<sup>nd</sup> AGM of the company.

#### As per TOR, We draw attention to the following matter:

1. The Company has started commercial operation of Steroid and Hormone project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42<sup>nd</sup> AGM. Total project cost of BDT 1,660,591,186 is generated from the IPO fund.

2. The Company has started commercial operation of Penicillin project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42<sup>nd</sup> AGM. Total project cost of BDT 400,000,000 is generated from the IPO fund.
3. The Company has also utilized accumulative amount of Tk. 354,120,593 up to 31 March 2020 in respect of API Project. During the month of March 2020, an amount of Tk.17,929,007 has been utilized out of IPO fund in respect of Active Pharmaceuticals Ingredients (API) Project.

**We also state that:**

- a) IPO proceeds have been utilized for the purposes as specified in the resolution of 42<sup>nd</sup> AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) API project, for which IPO fund was raised, will be completed within the time frame as specified in the resolution of 42<sup>nd</sup> AGM of the company.
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 42<sup>nd</sup> AGM of the company;
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Date: 07 June 2020  
Dhaka.

*Pinaki & Co*  
**Pinaki & Company**  
Chartered Accountants



Report on Utilization of IPO Proceeds  
For the Month of March 2020

Name of the Company: The ACME Laboratories Ltd.  
Amount (BDT) of capital raised through IPO: BDT 4,096,000,000 (Received amount BDT 4,095,015,601.38 net of foreign currency conversion loss)  
Date of Close of Subscription: 21 April 2016  
Proceeds Receiving Date: 11 April 2016 to 21 April 2016  
Last Date of Full Utilization of IPO Fund as per 40th AGM/42nd AGM: As stated in time line columns

S.L	Purpose mentioned in the 40th AGM/42nd AGM	Time Line		Cost Breakdown	Amount as per 40th AGM	Amount as per 42nd AGM	Opening	During the Month	Status of Utilization		Total un utilized amount	Un utilized %	Remarks
		As per 40th AGM	As per 42nd AGM						Total Utilized Amount	Utilized %			
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e., 2018	Within June 2019	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	335,800,000 598,600,000 339,600,000 39,500,000 5,000,000 26,300,000 13,200,000 1,358,000,000	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	334,934,878 933,900,000 353,700,000 21,986,000 5,000,000 1,200,000 9,870,308 1,660,591,186	-	334,934,878	100.00%	-	0.00%	Rearrangement of Utilization Plan has been approved in 42nd AGM as on 6 December 2018 and IPO Utilization Proceeds certified by M/s. Pinaki and Company, Chartered Accountants
2	Penicillin Project	Within the month of March 2018	Within June 2019	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Sub Total	116,000,000 132,299,520 117,154,000 20,582,700 3,000,000 5,963,780 5,000,000 400,000,000	142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 400,000,000	142,922,303 79,768,602 146,345,797 21,641,545 2,901,503 1,420,250 5,000,000 400,000,000	-	142,922,303	100.00%	-	0.00%	
3	Active Pharmaceuticals Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries	Within June 2022	Civil Construction Machinery & Equipment Utility Warehouse Vehicle Consultancy fee Contingencies Initial Working Capital Sub Total	347,860,000 493,000,000 409,400,000 38,500,000 3,000,000 23,635,200 12,917,600 26,915,492 1,355,228,292	355,637,304 250,495,241 - - - - - - 606,132,545	336,191,586 336,191,586 - - - - - - 17,929,007	17,929,007	354,120,593	99.57%	1,516,711	0.43%	
4	Repayment of Bank Borrowing at 40th AGM	N/A	N/A		1,360,000,000	1,360,000,000	1,360,000,000	-	1,360,000,000	100.00%	-	0.00%	
5	IPO Expenses	N/A	N/A		68,291,870	68,291,870	68,291,870	-	68,291,870	100.00%	-	0.00%	
Total					4,541,520,162	4,095,015,601	3,825,074,542	17,929,007	3,843,003,649	93.85%	252,011,952	6.15%	

Interest on IPO Proceeds in BDT (from FDR & SND)  
Un-Utilized IPO Proceeds with interest income in BDT

118,273,983  
370,285,935

On Behalf of Board

*(Signature)*  
Forza Haque, FCA  
Independent Director & Chairman of Audit Committee

*(Signature)*  
Nagim Afzal Sade  
Chairman  
(Nagim Afzal Sinha)

*(Signature)*  
Pinaki & Company  
Chartered Accountants